SCHEMBL998795

SCHEMBL998795

COc1ccc2[nH]c3c(c2c1)CCCN(C(=O)Nc1cccc(C)c1)C3C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
TP53 P04637 5/20 0.56
NPSR1 Q6W5P4 2/20 0.54
POLB P06746 2/20 0.50
SIRT1 Q96EB6 1/20 0.46
MAPKAPK2 P49137 5/20 0.45
KIF11 P52732 1/20 0.44
PAX8 Q06710 2/20 0.43
TRPV1 Q8NER1 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPKAPK5 Q8IW41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL997296 0.95 MAPT (0.62) MAPTTP53NPSR1POLBMAPKAPK2
SCHEMBL997581 0.89 MAPT (0.65) MAPTTP53NPSR1POLBMAPKAPK2
SCHEMBL998250 0.88 MAPT (0.71) MAPTTP53NPSR1POLBTRPV1
SCHEMBL997259 0.87 MAPT (0.67) MAPTTP53NPSR1POLBMEN1
SCHEMBL997020 0.86 MAPT (0.62) MAPTTP53NPSR1POLBMAPKAPK2
SCHEMBL998332 0.86 MAPT (0.74) MAPTTP53NPSR1POLBSIRT1
SCHEMBL998446 0.86 MAPT (0.64) MAPTTP53NPSR1POLBMAPKAPK2
SCHEMBL998021 0.86 MAPT (0.61) MAPTTP53NPSR1POLBMAPKAPK2
SCHEMBL999212 0.86 MAPT (0.61) MAPTTP53NPSR1POLBMAPKAPK2
SCHEMBL996817 0.85 MAPT (0.58) MAPTTP53NPSR1POLBSIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637521-B1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO (JP) 2013-06-19 EP disclosed
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed
EP-1637521-A1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS MAPT 4705/4885TP53 945/4885NPSR1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.